The new PsA filing is based on the results of two phase 3 trials of Tremfya – DISCOVER-1 and DISCOVER-2 – that met the primary endpoint of a 20% improvement in PsA symptoms (ACR 20 response ...

If you're interested in exploring more stocks under $20 get an edge over other traders with Benzinga Pro while we're currently offering a 14-day trial. Stocks under $20 offer investors and ...

Analysts at GlobalData have predicted that, fuelled by new indications, the two drugs could make peak combined sales of $32 billion by 2020, with Skyrizi accounting for around $20 billion of that ...

Spain 20 Year Government Bond-0.0040 3.9467% ...

The Estimates data displayed by Moneycontrol is not a recommendation to buy or sell any securities. Estimates data is a third party aggregated data provided by S&P Global Market Intelligence LLC ...

Treasury yields from 7 to 30 years out trade at or above 3%, a day after Fed delivers half-point rate hike ...

41 St. Joseph's Health Care London and University of Western Ontario, London, Ontario, Canada Objective The 1980 American College of Rheumatology (ACR) classification criteria for systemic sclerosis ...